. 2013 Aug 1;20(e2):e281–e287. doi: 10.1136/amiajnl-2013-001861

Table 2.

Exposures and outcomes of HA-CDI cases as compared to matched controls

Exposure or outcome	HA-CDI cases (n=362)	HA-CDI controls (n=362)	p Value	HR or OR (95% CI)
Length of stay, median (IQR), days	20 (13–33)	9 (6–14)	<0.001	0.34 (0.30 to 0.41)*
Length of stay, median (IQR), days	20 (13–33)	9 (6–14)	<0.001	0.33 (0.28 to 0.39)†
30-Day post-discharge mortality, no. (%)	80 (22)	42 (12)	0.05	1.48 (1.00 to 2.17)*
30-Day post-discharge mortality, no. (%)	80 (22)	42 (12)	0.10	1.38 (0.94 to 2.04)†
High-risk antibacterial exposure, no. (%)‡,§	240 (66)	124 (34)	<0.001	3.77 (2.74 to 5.20)¶
Low-risk antibacterial exposure, no. (%)‡,§	249 (69)	168 (46)	<0.001	2.54 (1.86 to 3.49)¶
PPI or H2-blocker exposure, no. (%)‡,§	297 (82)	265 (73)	0.006	1.67 (1.16 to 2.43)¶

*Unadjusted HR.

†Adjusted HR.

‡Medication POE data collected up to 24 h before diagnosis for cases, and for the first 48 h of healthcare exposure, for controls.

§Aggregate medication categories are defined in supplementary Table S2 (available online only).

¶OR.

HA-CDI, hospital-acquired C difficile; POE, provider order entry.